Organizational Update
Gilbert Announces George Hersbach to serve as Executive Chairman and Transition Role of CEO to Current COO Maurits Huigen. Click here for the full press release.
kenneth
About kenneth
Posts by :
Interview with Maurits Huigen
Interview with our COO Maurits Huigen after the nomination of Gilbert as one of the promising respiratory device solution providers by Medical Tech Outlook Magazine.
Funding for the development of a new generation soft mist inhalers for expensive medicines
The startup company Gilbert R&D B.V., a subsidiary of Gilbert B.V., announces today that it has received funding for the development of a new generation soft mist inhalers for the precise administration of expensive medicines for people with lung disease. Gilbert has received financing from Brabant Startup Fonds B.V. (“BSF”).
English: Click here for the full text press release.
Dutch: Click here for the full text press release.
Press release October 15, 2019
Belgium UCLouvain Louvain Drug Research Institute (LDRI) and Netherlands MedTech Start-up Gilbert join efforts for improved therapy for Cystic Fibrosis Patients.
LDRI receives funding for the development of a long-acting PEGylated rhDNase for CF-treatment with reduced therapeutic burden.
Click here for the full text press release.
Redefining Pulmonary Drug Administration and Therapy Adherence
MedTech Magazine, December 2018
When it comes to pulmonary drug administration and therapy adherence, it is noted that many of the commercially available inhalers such as Dry Powder Inhalers (DPIs) and Metered Dose Inhalers (MDIs) are relatively limited in their effectiveness. In this article, Maurits Huigen explains why and how Gilbert solves the limiting effects of current inhalers with a new finding using an electrospraying technique.
Read the full article published on Med Tech Outlook.